sNDA Submitted for Imbruvica

Share this content:
sNDA Submitted for Imbruvica
sNDA Submitted for Imbruvica

Janssen R&D and Pharmacyclics announced the submission of a supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib), based on positive data from the Phase 3 RESONATE study in relapsed or refractory chronic lymphocytic leukemia (CLL). Imbruvica, an antagonist of the Bruton's tyrosine kinase (BTK), inhibits cancer cell spread and proliferation by interrupting signals in B cells to mature and produce antibodies.

The Phase 3 PCYC-1112 (RESONATE) study is a randomized, multi-center, open-label study which enrolled patients with CLL or small lymphocytic lymphoma (SLL) (n=391) who received at least one prior therapy. The study compared once daily oral Imbruvica to intravenous ofatumumab in these patients. The trial was halted in January 2014 upon discovery of significant improvement in progression-free survival and overall survival with Imbruvica vs. ofatumumab during a pre-planned interim analysis.

RELATED: FDA Approves Ibrutinib for CLL

Imbruvica is already FDA approved for patients with CLL or mantle cell lymphoma (MCL) who received at least one prior therapy, and was among the first therapies in the US to receive FDA Breakthrough Therapy Designation.

For more information visit or

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs